Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
+1.69%
-1.09%
+1.10%
KPTI
Karyopharm Therapeutics
$5.99
Strengths
Upgraded on attractively valued
Earnings are forecast to grow
Technical Indicators
Pattern Watch
Chart
$7.48 (-19.92%)
$4.37 (+37.07%)
$4.53 (+32.23%)
$0.9 (+565.56%)
KPTI has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Low volume
High volatilty
KPTI overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
KPTI Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
KPTI Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
KPTI Earnings
The TTM reflects 12-month period, providing review of KPTI financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
What is KPTI current stock price?
What are KPTI stock strengths?
What risks are associated with KPTI stock?
When is KPTI next earnings report?
What is KPTI market cap and volume?
What is KPTI's current Stock IQ?
Should I buy KPTI stock right now?
Is KPTI a Strong Buy right now?
What does a 'Strong Buy' rating mean for KPTI?
What does a 'Strong Sell' rating mean for KPTI?
What factors influence KPTI's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+1.69%
-1.09%
+1.10%
KPTI
Karyopharm Therapeutics
Current Price
$5.99
Stock Insights
Strengths
Upgraded on attractively valued
Earnings are forecast to grow
Technical Indicators
Pattern Watch
Chart
$7.48 (-19.92%)
$4.37 (+37.07%)
$4.53 (+32.23%)
$0.9 (+565.56%)
KPTI Analysts Opinion
KPTI Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Below analyst estimate
Rating
Rating
Upgraded on attractively valued
Momentum
Momentum
Has been gaining momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
KPTI Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
KPTI Street view is extremely bullish and have positive views on the near-term outlook
KPTI has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Low volume
High volatilty
Average key support and resistance price levels.
KPTI Earnings
The TTM data reflects the most recent 12-month period, providing overview of KPTI financial performance.
KPTI Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
KPTI Latest Analysis
Karyopharm Therapeutics (KPTI)s Technical Outlook is Bright After Key Golden Cross. Is it a good or bad thing when a stock experiences a golden cross technical event?
Fri Oct 17, 2025
HC Wainwright & Co. Upgrades Karyopharm Therapeutics (KPTI). Fintel reports that on October 13 2025 HC Wainwright &. Co. upgraded their outlook for Karyopharm Therapeutics (NasdaqGS:KPTI) from Neutral to Buy. Analyst Price Forecast Suggests 226.40% Upside
Mon Oct 13, 2025
Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026. KPTI) on Wednesday announcedcomprehensive financing and capital structure transactions expected to provide the company with $100 million of financial flexibility and additional capital extending the cash runway into the second quarter of 2026.KPTI is among today’.s weakest performers. Karyopharm said it continues exploring potential financing and strategic alternatives to enhance liquidity and
Wed Oct 8, 2025
Karyopharm rises on securing $100M in financing to extend cash runway into Q2 2026.
Wed Oct 8, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
KPTI Stock trends
KPTI Stock performance
KPTI Stock analysis
KPTI investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.